Medicamen Biotech Analyst Review May 2026
- May 22, 2026
- Posted by: Kashish Aggarwal
- Category: News
This Medicamen Biotech analyst review for May 2026 covers the key data investors need for MEDICAME at its current price of Rs 125. Medicamen Biotech (NSE: MEDICAME) is a pharmaceutical company with a market capitalisation of approximately Rs 380 crore, manufacturing generic formulations and OTC healthcare products. The analyst consensus target of Rs 165 implies meaningful upside, and this Medicamen Biotech analyst review examines technical levels, business performance, valuation, and key risks for MEDICAME through FY27.
Click Here – Get Free Investment Predictions
Medicamen Biotech Company Snapshot May 2026
Medicamen Biotech produces branded generic formulations, OTC products, and nutraceuticals for domestic and export markets. The company has manufacturing capabilities in multiple dosage forms. The table below summarises the key data referenced in this Medicamen Biotech analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | MEDICAME |
| Sector | Pharmaceuticals – Generic Formulations |
| CMP (May 2026) | Rs 125 |
| 52 Week High | Rs 205 |
| 52 Week Low | Rs 95 |
| Market Cap | Rs 380 Crore |
| Trailing P/E | 18x |
| Analyst Consensus Target | Rs 165 |
| Bull Case Target | Rs 205 |
| Bear Case Target | Rs 108 |
Analyst Insight in This Medicamen Biotech Analyst Review
Senior Research Analyst Ankit Jaiswal flags Medicamen Biotech as a stock to watch in May 2026. At Rs 125, Ankit Jaiswal identifies key support in the Rs 96.90 to Rs 118.75 band and resistance near Rs 132.50. He suggests watching Medicamen Biotech for a potential move toward Rs 165, subject to Pharmaceuticals – Generic Formulations sector momentum. Ankit Jaiswal’s view is one input in this Medicamen Biotech analyst review and does not constitute a trade recommendation.
Technical Analysis in This Medicamen Biotech Analyst Review
At Rs 125, MEDICAME is trading within its 52-week band of Rs 95 to Rs 205. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 96.90 to Rs 118.75 band while resistance is seen in the Rs 132.50 to Rs 145.00 zone. A sustained move above Rs 132.50 could open the path toward the analyst consensus target of Rs 165 as identified in this Medicamen Biotech analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 96.90 to Rs 118.75 – investors tracking this Medicamen Biotech analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for MEDICAME.
- Resistance Zone: Rs 132.50 to Rs 145.00 – a sustained close above Rs 132.50 would be a positive breakout signal worth flagging in this Medicamen Biotech analyst review.
- Medium-Term Target: The analyst consensus of Rs 165 represents the base-case upside scenario in this Medicamen Biotech analyst review.
Business Segment Analysis
Branded Generic Formulations (Domestic Market)
This is the primary revenue and margin driver for Medicamen Biotech, directly supporting the earnings trajectory toward the consensus target of Rs 165.
OTC Healthcare and Nutraceutical Products
This segment adds scale and diversification to Medicamen Biotech’s business model and is a meaningful EPS contributor through FY27 and FY28.
Export Generic Formulations
This represents the medium-term growth frontier for Medicamen Biotech and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Medicamen Biotech Analyst Review
At Rs 125, Medicamen Biotech trades at a trailing P/E of 18x. This Medicamen Biotech analyst review presents three scenarios: a bull case of Rs 205 on strong earnings delivery, a base case of Rs 165 at analyst consensus, and a bear case of Rs 108 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Medicamen Biotech analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 205 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 165 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 108 | Earnings miss or macro headwinds |
Trade Outlook for Medicamen Biotech
Based on the technical and fundamental analysis in this Medicamen Biotech analyst review, investors might watch MEDICAME near the support zone of Rs 96.90 to Rs 118.75 for potential opportunities. A flag above Rs 132.50 could suggest improving momentum toward Rs 165. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Medicamen Biotech in FY27
A well-rounded Medicamen Biotech analyst review must assess downside risks. Key risks for Medicamen Biotech include a macro slowdown affecting Pharmaceuticals – Generic Formulations sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in MEDICAME.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Medicamen Biotech Analyst Review Verdict for 2026
This Medicamen Biotech analyst review concludes that at Rs 125, MEDICAME offers a defined risk-reward with a consensus target of Rs 165. The 52-week range of Rs 95 to Rs 205 provides context on the current entry point. Use this Medicamen Biotech analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on MEDICAME.
Frequently Asked Questions: Medicamen Biotech Analyst Review 2026
What is the analyst target for Medicamen Biotech in 2026?
The analyst consensus target is Rs 165, with a bull case of Rs 205 and a bear case of Rs 108. This Medicamen Biotech analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is Medicamen Biotech a good investment at Rs 125?
At Rs 125 with a P/E of 18x and a consensus target of Rs 165, this Medicamen Biotech analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Generic Formulations sector. Always consult a SEBI-registered advisor before investing.
What is Medicamen Biotech’s 52-week high and low?
The 52-week high is Rs 205 and the 52-week low is Rs 95. At Rs 125, MEDICAME is positioned within this range as noted in this Medicamen Biotech analyst review.
What are the key risks for Medicamen Biotech?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Generic Formulations sector as assessed in this Medicamen Biotech analyst review.
Where can I track live data for Medicamen Biotech?
Track Medicamen Biotech’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Medicamen Biotech analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
